The University of Tokyo

Chugai Seiyaku Kabushiki Kaisha

Perseus Proteomics Inc.

Other

Sysmex Corporation

Forerunner Pharma Research Co., Ltd.

Haplopharma Inc.

Tetsuo Nakamura

Aburatani, Hiroyuki

Masayuki Tsuchiya

Hiroyuki Aburatani

Shumpei Ishikawa

Hirotaka Ito

Yukio Ito

Yoshitaka Hippo

Toshihiko Ohtomo

Hiroko Iwanari

Shigeto Kawai

Hirokazu Taniguchi

Kiyotaka Nakano

Shogo Yamamoto

Isao Kohno

Yong Xin Chen

Shin-ichi Fukumoto

Takahiro Shimamura

Ying Qiu Guo

Shunpei Ishikawa

Kenji Yoshida

Akira Watanabe

Masahiro Arai

Keisuke Ishii

Takao Hamakubo

Yasuko Kinoshita

Shin-Ichi Funahashi

Hiroshi Onishi

Katsushi Kouda

Yoko Kayukawa

Susumu Tokita

Naoko Kamimura

Shuichi Tsutsumi

Masahiro Kajita

Lilin Zhang

Keiko Katsumi

Hirotaka Itoh

Shinichi Funahashi

Masashi Fukayama

Aya Sakamoto

Yutaka Midorikawa

Ayako Sakai

Kunihiro Nishimura

Iwao Ohizumi

Hirokazu Satoh

Toshimitsu Momose

Yasuhiro Mochizuki

Takashi Nishizawa

Kaya Tai

Genta Nagae

Naoka Kamimura

Hirofumi Sakumoto

Shunsuke Niwa

Yoshiko Nakada

Atsushi Kaneda

Kouichi Yagi

Shin-ichi Funahashi

Shin-ichi Funahshi

Miwako Kakiuchi

Yuriko Uehara

Yoshitaka Kumakura

Toshiko Sakihama

Kiyotaka Watanabe

Shin Ohnishi

Shin-Ichi Fukumoto

Toshihiko c/o Chugai Seiyaku K K Ohtomo

Yukio c/o Perseus Proteomics Inc Ito

Hirotaka c/o Chugai Seiyaku K K Ito

It is intended to disclose an antibody which binds to DLL3 protein. Preferably, the antibody of the present invention recognizes a region from amino acids 216 to 492 in human DLL3 having the amino acid sequence as set forth in SEQ ID NO: 1. The present invention also provides a pharmaceutical composition, for example, an anticancer agent, comprising the antibody of the present invention as an active ingredient. The present invention further discloses a method for diagnosing cancer using the antibody of the present invention and a diagnostic drug for cancer comprising the antibody of the present invention.

Anti-DLL3 antibody

Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes a DSG3 protein. Pharmaceutical compositions, cell growth inhibitors, and anticancer agents containing a DSG3-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in DSG3-expressing cells and methods of suppressing proliferation of DSG3-expressing cells by contacting the DSG3-expressing cells with DSG3-binding antibodies are also disclosed.

Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies

Disclosed are a novel method of detecting cancer, a method of screening inhibitors and anticancer agents that target cancer-related molecules, RHOA polypeptide having mutation and a polynucleotide encoding the polypeptide as a therapeutic agent for cancer, and a method of detecting cancer using the polypeptide or polynucleotide. Also disclosed are a vector and a host cell comprising the polynucleotide, a method of screening therapeutic agents for cancer comprising the polypeptide and/or the polynucleotide, and a therapeutic agent for cancer comprising siRNA having a silencing effect on RHOA mutant.

Use of RHOA in cancer diagnosis and inhibitor screening

A determination device for enabling a computer to carry out a process including the steps of: obtaining an analysis result on methylation status of a CpG site located in a promoter region of at least one gene selected from HOXB4 (Homeobox B4) and ZSCAN31 (zinc finger and SCAN domain containing 31) in a DNA sample derived from a subject; and outputting a determination result as information on lung cancer in the subject based on the resulting analysis result is provided. A computer readable medium and a marker for obtaining information on lung cancer are also provided.

Determination device, computer readable medium, and marker for obtaining information on lung cancer

Disclosed is a monoclonal antibody binding to an ITM2A protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as Ewing's sarcoma, T cell leukemia, T cell lymphoma, acute myeloid leukemia, B cell tumor, and multiple myeloma. The present invention also provides a pharmaceutical composition, a cell growth inhibitor, and an anticancer agent containing the antibody as an active ingredient, and a method for treating cancer, a method for predicting the efficacy of cancer treatment, and a method for determining the presence of cancer in a test subject using the antibody.

Diagnosis and treatment of cancer using anti-ITM2A antibody

A method for diagnosing cancer comprising detecting ROBO1 protein is disclosed. In addition, a method for treating a disease caused by abnormal cell growth comprising administrating an antibody that binds to ROBO1, as well as a pharmaceutical composition, a cell growth inhibitor and an anticancer agent comprising an antibody that binds to ROBO1 as an active ingredient are disclosed. Further, a method for inducing cell damages in a ROBO1 expressing cell and a method for inhibiting the growth of a ROBO1 expressing cell by bringing a ROBO1 expressing cell into contact with an antibody that binds to ROBO1, are disclosed. Furthermore, a method for monitoring progression of hepatitis by detecting ROBO1 protein is disclosed.

Cancer diagnosis and treatment of cancer using anti-ROBO1 antibody

Provided is a method for diagnosing cancer by detecting a novel cancer marker. Cancer can be diagnosed by detecting soluble glypican 3 in a test sample.

Method for diagnosing cancer by detecting GPC3

Disclosed are a protein encoded by a gene having a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a fragment thereof, an antibody recognizing the protein or antigen-binding fragment thereof, and a polynucleotide having a sequence comprising at least 12 consecutive nucleotides of a nucleotide sequence represented by any of SEQ ID NOs: 1 to 65 or a nucleotide sequence complementary thereto. The gene and the protein of the invention is useful for diagnosing and treating cancer.

Gene overexpressed in cancer

The present invention relates to an antibody binding to Claudin6 (CLDN6) expressed on a cell membrane. The antibody of the present invention recognizes human CLDN6 present in a native form on cell membrane surface and exhibits cytotoxicity through ADCC and/or CDC activities against cancer cell lines highly expressing human CLDN6. Moreover, the antibody of the present invention has cell growth inhibitory effect through conjugation with toxin on cancer cell lines highly expressing human CLDN6. The human CLDN6 is overexpressed in tumor tissues (lung adenocarcinoma, gastric cancer, and ovarian cancer), although its expression is not observed in normal tissues. Thus, the anti-CLDN6 antibody is expected to highly accumulate in tumors highly expressing human CLDN6 and can serve as a very effective antitumor agent.

Anti-CLDN6 antibody

[Theme] To provide a monoclonal antibody against human GPR87. Also, to provide a novel means for diagnosing or treating a malignant tumor. [Solution means] Monoclonal antibodies against human GPR87 are provided. The antibodies can recognize human GPR87, which is expressed on a cell membrane while retaining a three-dimensional structure, and can recognize GPR87, which is expressed in a cell endogenously with an epitope being present in an extracellular domain of full-length human GPR87. The antibodies are thus useful in biochemical analysis, etc., of GPR87, useful in immunohistological diagnosis, etc., of squamous cell carcinoma, and also potentially useful in PET diagnosis, antibodies for treatment, etc., of squamous cell carcinoma.

Monoclonal antibody, and use thereof

The present invention relates to an antibody binding to a TM4SF20 protein and the diagnosis and treatment of cancer using the antibody. Specifically, the present invention provides an anti-TM4SF20 antibody and a pharmaceutical composition (e.g., an anticancer agent and a diagnostic drug for cancer) comprising the antibody as an active ingredient.

Diagnosis and treatment of cancer using anti-TM4SF20 antibody

[Problem to be Solved] An object of the present invention is to provide novel means for the treatment and diagnosis of cancer. [Solution] The present inventors have obtained a monoclonal antibody against TMPRSS11E and found that this antibody binds to a native form of TMPRSS11E, and TMPRSS11E is highly expressed on the cell membranes of cancer cell lines in flow cytometry. This antibody exhibits antibody-dependent cell-mediated cytotoxicity activity (ADCC activity) and antitumor effect based on internalization activity and is promising as a therapeutic target. Moreover, this antibody has neutralization activity against protease activity and is also expected to have effect brought about by the inhibition of TMPRSS11E functions.

Diagnosis and treatment of cancer using anti-TMPRSS11E antibody

The present invention relates to a method for determination of the presence or absence of cancer cells in a biological sample or a method for determination of the prognosis of a colorectal cancer patient based on a result obtained by extracting DNA from a biological sample and analyzing methylation status of a marker gene in the DNA.

Methylation analysis to determine the presence of cancer cells

Growing community of inventors

Tokyo, Japan

Hiroyuki Aburatani